The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart

ISSN:
1432-1041
Keywords:
Key words Mibefradil; refractory periods ; electro physiology ; atrioventricular node ; calcium antagonist
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
Medicine
Notes:
Abstract Objective : This multicenter, double-blind, placebo-controlled, parallel-group study was designed to assess the acute effects of intravenous mibefradil on the electrophysiologic characteristics of the human heart. Methods : Seventy-one patients referred for routine electrophysiologic testing were randomized to receive one of three intravenous treatments: placebo $n=23$ , 15 mg mibefradil in 15 min followed by 25 mg in 60 min (group 1, $n=24$ ), or 35 mg mibefradil in 15 min followed by 45 mg in 60 min (group 2, $n=24$ ). Electrophysiologic evaluations were performed prior to study drug administration and 30 min after the start of the infusion. Plasma samples were obtained at the start of the infusion and after 15, 75, and 105 min. Results : Sinus node recovery time decreased significantly in Group 1 patients (−103 ms). Corrected sinus node recovery time in group 2 patients was 68.7 ms $(P=0.053)$ . Compared to placebo, mibefradil produced mild but significant slowing of conduction in group 2 patients as manifested by an increase in the AH interval of 6.7 ms. Atrioventricular (AV) nodal refractoriness was increased, as indicated by a prolongation of the Wenckebach point in patients in both group 1 (32.1 ms) and group 2 (32.5 ms), compared to placebo. All adverse events were classified as mild to moderate and only one event (vasovagal attack) was considered to be treatment related. Conclusions : At plasma levels close to those found after chronic oral administration of 50 and 100 mg mibefradil, the higher dose produced an increase in corrected sinus node recovery time. Mibefradil also produced small but significant effects on AV nodal conduction and increased AV nodal refractoriness. Mibefradil had no effect on any other electrophysiologic parameter and was well tolerated.
Type of Medium:
Electronic Resource
URL:
_version_ 1798295570905825280
autor Rosenquist, M.
Brembilla-Perrot, B.
Meinertz, T.
Neugebauer, A.
Crijns, H. J. M. G.
Smeets, J. L. R. M.
van der Vring, J. A. F. M.
Fromer, M.
Kobrin, I.
autorsonst Rosenquist, M.
Brembilla-Perrot, B.
Meinertz, T.
Neugebauer, A.
Crijns, H. J. M. G.
Smeets, J. L. R. M.
van der Vring, J. A. F. M.
Fromer, M.
Kobrin, I.
book_url http://dx.doi.org/10.1007/s002280050241
datenlieferant nat_lic_papers
hauptsatz hsatz_simple
identnr NLM20247657X
issn 1432-1041
journal_name European journal of clinical pharmacology
materialart 1
notes Abstract Objective : This multicenter, double-blind, placebo-controlled, parallel-group study was designed to assess the acute effects of intravenous mibefradil on the electrophysiologic characteristics of the human heart. Methods : Seventy-one patients referred for routine electrophysiologic testing were randomized to receive one of three intravenous treatments: placebo $n=23$ , 15 mg mibefradil in 15 min followed by 25 mg in 60 min (group 1, $n=24$ ), or 35 mg mibefradil in 15 min followed by 45 mg in 60 min (group 2, $n=24$ ). Electrophysiologic evaluations were performed prior to study drug administration and 30 min after the start of the infusion. Plasma samples were obtained at the start of the infusion and after 15, 75, and 105 min. Results : Sinus node recovery time decreased significantly in Group 1 patients (−103 ms). Corrected sinus node recovery time in group 2 patients was 68.7 ms $(P=0.053)$ . Compared to placebo, mibefradil produced mild but significant slowing of conduction in group 2 patients as manifested by an increase in the AH interval of 6.7 ms. Atrioventricular (AV) nodal refractoriness was increased, as indicated by a prolongation of the Wenckebach point in patients in both group 1 (32.1 ms) and group 2 (32.5 ms), compared to placebo. All adverse events were classified as mild to moderate and only one event (vasovagal attack) was considered to be treatment related. Conclusions : At plasma levels close to those found after chronic oral administration of 50 and 100 mg mibefradil, the higher dose produced an increase in corrected sinus node recovery time. Mibefradil also produced small but significant effects on AV nodal conduction and increased AV nodal refractoriness. Mibefradil had no effect on any other electrophysiologic parameter and was well tolerated.
package_name Springer
publikationsjahr_anzeige 1997
publikationsjahr_facette 1997
publikationsjahr_intervall 8004:1995-1999
publikationsjahr_sort 1997
publisher Springer
reference 52 (1997), S. 7-12
schlagwort Key words Mibefradil; refractory periods
electro physiology
atrioventricular node
calcium antagonist
search_space articles
shingle_author_1 Rosenquist, M.
Brembilla-Perrot, B.
Meinertz, T.
Neugebauer, A.
Crijns, H. J. M. G.
Smeets, J. L. R. M.
van der Vring, J. A. F. M.
Fromer, M.
Kobrin, I.
shingle_author_2 Rosenquist, M.
Brembilla-Perrot, B.
Meinertz, T.
Neugebauer, A.
Crijns, H. J. M. G.
Smeets, J. L. R. M.
van der Vring, J. A. F. M.
Fromer, M.
Kobrin, I.
shingle_author_3 Rosenquist, M.
Brembilla-Perrot, B.
Meinertz, T.
Neugebauer, A.
Crijns, H. J. M. G.
Smeets, J. L. R. M.
van der Vring, J. A. F. M.
Fromer, M.
Kobrin, I.
shingle_author_4 Rosenquist, M.
Brembilla-Perrot, B.
Meinertz, T.
Neugebauer, A.
Crijns, H. J. M. G.
Smeets, J. L. R. M.
van der Vring, J. A. F. M.
Fromer, M.
Kobrin, I.
shingle_catch_all_1 Rosenquist, M.
Brembilla-Perrot, B.
Meinertz, T.
Neugebauer, A.
Crijns, H. J. M. G.
Smeets, J. L. R. M.
van der Vring, J. A. F. M.
Fromer, M.
Kobrin, I.
The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart
Key words Mibefradil; refractory periods
electro physiology
atrioventricular node
calcium antagonist
Key words Mibefradil; refractory periods
electro physiology
atrioventricular node
calcium antagonist
Abstract Objective : This multicenter, double-blind, placebo-controlled, parallel-group study was designed to assess the acute effects of intravenous mibefradil on the electrophysiologic characteristics of the human heart. Methods : Seventy-one patients referred for routine electrophysiologic testing were randomized to receive one of three intravenous treatments: placebo $n=23$ , 15 mg mibefradil in 15 min followed by 25 mg in 60 min (group 1, $n=24$ ), or 35 mg mibefradil in 15 min followed by 45 mg in 60 min (group 2, $n=24$ ). Electrophysiologic evaluations were performed prior to study drug administration and 30 min after the start of the infusion. Plasma samples were obtained at the start of the infusion and after 15, 75, and 105 min. Results : Sinus node recovery time decreased significantly in Group 1 patients (−103 ms). Corrected sinus node recovery time in group 2 patients was 68.7 ms $(P=0.053)$ . Compared to placebo, mibefradil produced mild but significant slowing of conduction in group 2 patients as manifested by an increase in the AH interval of 6.7 ms. Atrioventricular (AV) nodal refractoriness was increased, as indicated by a prolongation of the Wenckebach point in patients in both group 1 (32.1 ms) and group 2 (32.5 ms), compared to placebo. All adverse events were classified as mild to moderate and only one event (vasovagal attack) was considered to be treatment related. Conclusions : At plasma levels close to those found after chronic oral administration of 50 and 100 mg mibefradil, the higher dose produced an increase in corrected sinus node recovery time. Mibefradil also produced small but significant effects on AV nodal conduction and increased AV nodal refractoriness. Mibefradil had no effect on any other electrophysiologic parameter and was well tolerated.
1432-1041
14321041
Springer
shingle_catch_all_2 Rosenquist, M.
Brembilla-Perrot, B.
Meinertz, T.
Neugebauer, A.
Crijns, H. J. M. G.
Smeets, J. L. R. M.
van der Vring, J. A. F. M.
Fromer, M.
Kobrin, I.
The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart
Key words Mibefradil; refractory periods
electro physiology
atrioventricular node
calcium antagonist
Key words Mibefradil; refractory periods
electro physiology
atrioventricular node
calcium antagonist
Abstract Objective : This multicenter, double-blind, placebo-controlled, parallel-group study was designed to assess the acute effects of intravenous mibefradil on the electrophysiologic characteristics of the human heart. Methods : Seventy-one patients referred for routine electrophysiologic testing were randomized to receive one of three intravenous treatments: placebo $n=23$ , 15 mg mibefradil in 15 min followed by 25 mg in 60 min (group 1, $n=24$ ), or 35 mg mibefradil in 15 min followed by 45 mg in 60 min (group 2, $n=24$ ). Electrophysiologic evaluations were performed prior to study drug administration and 30 min after the start of the infusion. Plasma samples were obtained at the start of the infusion and after 15, 75, and 105 min. Results : Sinus node recovery time decreased significantly in Group 1 patients (−103 ms). Corrected sinus node recovery time in group 2 patients was 68.7 ms $(P=0.053)$ . Compared to placebo, mibefradil produced mild but significant slowing of conduction in group 2 patients as manifested by an increase in the AH interval of 6.7 ms. Atrioventricular (AV) nodal refractoriness was increased, as indicated by a prolongation of the Wenckebach point in patients in both group 1 (32.1 ms) and group 2 (32.5 ms), compared to placebo. All adverse events were classified as mild to moderate and only one event (vasovagal attack) was considered to be treatment related. Conclusions : At plasma levels close to those found after chronic oral administration of 50 and 100 mg mibefradil, the higher dose produced an increase in corrected sinus node recovery time. Mibefradil also produced small but significant effects on AV nodal conduction and increased AV nodal refractoriness. Mibefradil had no effect on any other electrophysiologic parameter and was well tolerated.
1432-1041
14321041
Springer
shingle_catch_all_3 Rosenquist, M.
Brembilla-Perrot, B.
Meinertz, T.
Neugebauer, A.
Crijns, H. J. M. G.
Smeets, J. L. R. M.
van der Vring, J. A. F. M.
Fromer, M.
Kobrin, I.
The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart
Key words Mibefradil; refractory periods
electro physiology
atrioventricular node
calcium antagonist
Key words Mibefradil; refractory periods
electro physiology
atrioventricular node
calcium antagonist
Abstract Objective : This multicenter, double-blind, placebo-controlled, parallel-group study was designed to assess the acute effects of intravenous mibefradil on the electrophysiologic characteristics of the human heart. Methods : Seventy-one patients referred for routine electrophysiologic testing were randomized to receive one of three intravenous treatments: placebo $n=23$ , 15 mg mibefradil in 15 min followed by 25 mg in 60 min (group 1, $n=24$ ), or 35 mg mibefradil in 15 min followed by 45 mg in 60 min (group 2, $n=24$ ). Electrophysiologic evaluations were performed prior to study drug administration and 30 min after the start of the infusion. Plasma samples were obtained at the start of the infusion and after 15, 75, and 105 min. Results : Sinus node recovery time decreased significantly in Group 1 patients (−103 ms). Corrected sinus node recovery time in group 2 patients was 68.7 ms $(P=0.053)$ . Compared to placebo, mibefradil produced mild but significant slowing of conduction in group 2 patients as manifested by an increase in the AH interval of 6.7 ms. Atrioventricular (AV) nodal refractoriness was increased, as indicated by a prolongation of the Wenckebach point in patients in both group 1 (32.1 ms) and group 2 (32.5 ms), compared to placebo. All adverse events were classified as mild to moderate and only one event (vasovagal attack) was considered to be treatment related. Conclusions : At plasma levels close to those found after chronic oral administration of 50 and 100 mg mibefradil, the higher dose produced an increase in corrected sinus node recovery time. Mibefradil also produced small but significant effects on AV nodal conduction and increased AV nodal refractoriness. Mibefradil had no effect on any other electrophysiologic parameter and was well tolerated.
1432-1041
14321041
Springer
shingle_catch_all_4 Rosenquist, M.
Brembilla-Perrot, B.
Meinertz, T.
Neugebauer, A.
Crijns, H. J. M. G.
Smeets, J. L. R. M.
van der Vring, J. A. F. M.
Fromer, M.
Kobrin, I.
The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart
Key words Mibefradil; refractory periods
electro physiology
atrioventricular node
calcium antagonist
Key words Mibefradil; refractory periods
electro physiology
atrioventricular node
calcium antagonist
Abstract Objective : This multicenter, double-blind, placebo-controlled, parallel-group study was designed to assess the acute effects of intravenous mibefradil on the electrophysiologic characteristics of the human heart. Methods : Seventy-one patients referred for routine electrophysiologic testing were randomized to receive one of three intravenous treatments: placebo $n=23$ , 15 mg mibefradil in 15 min followed by 25 mg in 60 min (group 1, $n=24$ ), or 35 mg mibefradil in 15 min followed by 45 mg in 60 min (group 2, $n=24$ ). Electrophysiologic evaluations were performed prior to study drug administration and 30 min after the start of the infusion. Plasma samples were obtained at the start of the infusion and after 15, 75, and 105 min. Results : Sinus node recovery time decreased significantly in Group 1 patients (−103 ms). Corrected sinus node recovery time in group 2 patients was 68.7 ms $(P=0.053)$ . Compared to placebo, mibefradil produced mild but significant slowing of conduction in group 2 patients as manifested by an increase in the AH interval of 6.7 ms. Atrioventricular (AV) nodal refractoriness was increased, as indicated by a prolongation of the Wenckebach point in patients in both group 1 (32.1 ms) and group 2 (32.5 ms), compared to placebo. All adverse events were classified as mild to moderate and only one event (vasovagal attack) was considered to be treatment related. Conclusions : At plasma levels close to those found after chronic oral administration of 50 and 100 mg mibefradil, the higher dose produced an increase in corrected sinus node recovery time. Mibefradil also produced small but significant effects on AV nodal conduction and increased AV nodal refractoriness. Mibefradil had no effect on any other electrophysiologic parameter and was well tolerated.
1432-1041
14321041
Springer
shingle_title_1 The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart
shingle_title_2 The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart
shingle_title_3 The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart
shingle_title_4 The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart
sigel_instance_filter dkfz
geomar
wilbert
ipn
albert
fhp
source_archive Springer Online Journal Archives 1860-2000
timestamp 2024-05-06T09:38:19.269Z
titel The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart
titel_suche The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart
topic V
WW-YZ
uid nat_lic_papers_NLM20247657X